Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol
Safe Stop IPI-NIVO 试验:对于接受一线伊匹木单抗-纳武单抗治疗的不可切除的 III 期或转移性黑色素瘤患者,在达到完全缓解或部分缓解后早期停止纳武单抗治疗——研究方案
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12336-0
Janssen, J C; van Dijk, B; de Joode, K; Aarts, M J B; van den Berkmortel, F W P J; Blank, C U; Boers-Sonderen, M J; van den Eertwegh, A J M; de Groot, J W B; Jalving, M; de Jonge, M J A; Joosse, A; Kapiteijn, E; Kamphuis-Huismans, A M; Naipal, K A T; Piersma, D; Rikhof, B; Westgeest, H M; Vreugdenhil, G; Oomen-de Hoop, E; Mulder, E E A P; van der Veldt, Astrid A M